logo
Trump Budget Draft Ends Narcan Program and Other Addiction Measures

Trump Budget Draft Ends Narcan Program and Other Addiction Measures

New York Times25-04-2025

The opioid overdose reversal medication commercially known as Narcan saves hundreds of thousands of lives a year and is routinely praised by public health experts for contributing to the continuing drop in opioid-related deaths. But the Trump administration plans to terminate a $56 million annual grant program that distributes doses and trains emergency responders in communities across the country to administer them, according to a draft budget proposal.
In the document, which outlines details of the drastic reorganization and shrinking planned for the Department of Health and Human Services, the grant is among many addiction prevention and treatment programs to be zeroed out.
States and local governments have other resources for obtaining doses of Narcan, which is also known by its generic name, naloxone. One of the main sources, a program of block grants for states to use to pay for various measures to combat opioid addiction, does not appear to have been cut.
But addiction specialists are worried about the symbolic as well as practical implications of shutting down a federal grant designated specifically for naloxone training and distribution.
'Reducing the funding for naloxone and overdose prevention sends the message that we would rather people who use drugs die than get the support they need and deserve,' said Dr. Melody Glenn, an addiction medicine physician and assistant professor at the University of Arizona, who monitors such programs along the state's southern border.
Neither the Department of Health and Human Services nor the White House's drug policy office responded to requests for comment.
Although budget decisions are not finalized and could be adjusted, Dr. Glenn and others see the fact that the Trump administration has not even opened applications for new grants as another indication that the programs may be eliminated.
Other addiction-related grants on the chopping block include those offering treatment for pregnant and postpartum women; peer support programs typically run by people who are in recovery; a program called the 'youth prevention and recovery initiative'; and programs that develop pain management protocols for emergency departments in lieu of opioids.
The federal health secretary, Robert F. Kennedy Jr., has long shown a passionate interest in addressing the drug crisis and has been outspoken about his own recovery from heroin addiction. The proposed elimination of addiction programs seems at odds with that goal. Last year, Mr. Kennedy's presidential campaign produced a documentary that outlined federally supported pathways out of addiction.
The grants were awarded through the Substance Abuse and Mental Health Services Administration, an agency within the federal health department that would itself be eliminated under the draft budget proposal, though some of its programs would continue under a new entity, the Administration for a Healthy America.
In 2024, recipients of the naloxone grants, including cities, tribes and nonprofit groups, trained 66,000 police officers, fire fighters and emergency medical responders, and distributed over 282,500 naloxone kits, according to a spokesman for the substance abuse agency.
'Narcan has been kind of a godsend as far as opioid epidemics are concerned, and we are certainly are in the middle of one now with fentanyl,' said Donald McNamara, who oversees naloxone procurement and training for the Los Angeles County Sheriff's Department. 'We need this funding source because it's saving lives every day.'
Matthew Cushman, a fire department paramedic in Raytown, Mo., said that through the naloxone grant program, he had trained thousands of police officers, firefighters and emergency medical responders throughout Kansas City and western rural areas. The program provides trainees with pouches of naloxone to administer in the field plus 'leave behind' kits with information about detox and treatment clinics.
In 2023, federal figures started to show that national opioid deaths were finally declining, progress that many public health experts attribute in some measure to wider availability of the drug, which the Food and Drug Administration approved for over-the-counter sales that year.
Tennessee reports that between 2017 and 2024, 103,000 lives saved were directly attributable to naloxone. In Kentucky, which trains and supplies emergency medical workers in 68 rural communities, a health department spokeswoman noted that in 2023, overdose fatalities dropped by nearly 10 percent.
And though the focus of the Trump administration's Office of National Drug Control Policy is weighted toward border policing and drug prosecutions, its priorities, released in an official statement this month, include the goal of expanding access to 'lifesaving opioid overdose reversal medications like naloxone.'
'They immediately reference how much they want to support first responders and naloxone distribution,' said Rachel Winograd, director of the addiction science team at the University of Missouri-St. Louis, who oversees the state's federally funded naloxone program. 'Juxtaposing those statements of support with the proposed eliminations is extremely confusing.'
Mr. Cushman, the paramedic in Missouri, said that ending the naloxone grant program would not only cut off a source of the medication to emergency responders but would also stop classes that do significantly more than teach how to administer it.
His cited the insights offered by his co-instructor, Ray Rath, who is in recovery from heroin and is a certified peer support counselor. In training sessions, Mr. Rath recounts how, after a nasal spray of Narcan yanked him back from a heroin overdose, he found himself on the ground, looking up at police officers and emergency medical responders. They were snickering.
'Ah this junkie again, he's just going to kill himself; we're out here for no reason,' he recalled them saying.
Mr. Rath said he speaks with trainees about how the individuals they revive are 'people that have an illness.'
'And once we start treating them like people, they feel like people,' he continued. 'They feel cared about, and they want to make a change.'
He estimated that during the years he used opioids, naloxone revived him from overdoses at least 10 times. He has been in recovery for five years, a training instructor for the last three. He also works in homeless encampments in Kansas, offering services to people who use drugs. The back of his T-shirt reads: 'Hope Dealer.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Federal judge rules Tump directives canceling NIH grants are 'void,' 'illegal'

time3 hours ago

Federal judge rules Tump directives canceling NIH grants are 'void,' 'illegal'

A federal judge in Massachusetts ruled on Monday that directives from the Trump administration that led to the cancellations of several research grants from the National Institutes of Health (NIH) were "void" and "illegal." U.S. District Judge William Young said the cancellation of the grants -- related to studies involving LGBTQ+ issues, gender identity and diversity, equity and inclusion (DEI) -- violated federal law, saying it was a case of racial discrimination and discrimination against the LGBTQ+ community, according to the plaintiffs in the case. Two lawsuits had been filed against the administration: One led by the American Public Health Association and the other filed by a group of 16 states. Some estimates have suggested that up to $1.8 billion in research funding had been cut. Young, an appointee of President Ronald Reagan, said he was ordering the NIH to restore the grants that were terminated. In a statement, Andrew Nixon, the director of communications for the Department of Health and Human Services, said the agency stands by its decision to end funding for research "that prioritized ideological agendas over scientific rigor and meaningful outcomes for the American people. Under the leadership of Secretary Kennedy and the Trump administration, HHS is committed to ensuring that taxpayer dollars support programs rooted in evidence-based practices and gold standard science – not driven by divisive DEI mandates or gender ideology." Nixon said HHS is "exploring all legal options, including filing an appeal and moving to stay the order." Among the plaintiffs is Dr. Brittany Charlton, an associate professor at Harvard T.H. Chan School of Public Health, who had all her grants terminated by the NIH. One of the terminated grants focused on documenting obstetrical outcomes for lesbian, gay and bisexual women and another focused on how discriminatory laws impact mental health among LGBTQ+ teens. "As a plaintiff, I felt truly seen -- it was a rare moment when the deep harm caused to researchers and the communities we serve was acknowledged out loud, in front of the world," Charlton told ABC News in a statement. "Sitting there, I felt a wave of relief and hope as the judge condemned the government's actions and ordered the grants to be reinstated," the statement continued. "After so much uncertainty and disruption, it finally felt like justice and the value of our research -- and the communities at its heart -- were being affirmed." The terminations came after President Donald Trump passed a flurry of executive orders including vowing to " defend women from gender ideology extremism" and aiming to dismantle DEI initiatives. According to termination letters sent to researchers at various universities that were reviewed by ABC News, the administration said the canceled projects do not serve the "priorities" of the current administration. "Research programs based on gender identity are often unscientific, have little identifiable return on investment, and do nothing to enhance the health of many Americans. Many such studies ignore, rather than seriously examine, biological realities. It is the policy of NIH not to prioritize these research programs," some of the termination letters read. "The premise…is incompatible with agency priorities, and no modification of the project could align the project with agency priorities," the letters continued.

Senate Republicans abandon Medicare cost cuts, Bloomberg reports
Senate Republicans abandon Medicare cost cuts, Bloomberg reports

Business Insider

time4 hours ago

  • Business Insider

Senate Republicans abandon Medicare cost cuts, Bloomberg reports

Senate Republicans are proposing cuts to Medicaid for low-income and disabled people that are more aggressive than policies the House passed to help pay for President Trump's tax package, Rachel Cohrs Zhang of Bloomberg reports, citing people familiar with the legislation. Senate Republicans, however, abandoned efforts to cut costs in Medicare, which is good news for Humana (HUM) and UnitedHealth (UNH), which are major players in the Medicare Advantage insurance market, according to Bloomberg. The Senate plan, to be be released on Monday, solidifies Republicans' decision to cut funding for Medicaid health insurance for the poor to pay for tax cuts, Bloomberg adds. Publicly traded companies in the space health insurance space include CVS Health (CVS), Centene (CNC), Cigna (CI), Elevance Health (ELV), Humana (HUM), Molina Healthcare (MOH) and UnitedHealth (UNH). Confident Investing Starts Here:

Judge rules some NIH grant cuts illegal, saying he's never seen such discrimination in 40 years
Judge rules some NIH grant cuts illegal, saying he's never seen such discrimination in 40 years

Los Angeles Times

time7 hours ago

  • Los Angeles Times

Judge rules some NIH grant cuts illegal, saying he's never seen such discrimination in 40 years

WASHINGTON — A federal judge ruled Monday it was illegal for the Trump administration to cancel several hundred research grants, adding that the cuts raise serious questions about racial discrimination. U.S. District Judge William Young in Massachusetts said the administration's process was 'arbitrary and capricious' and that it did not follow long-held government rules and standards when it abruptly canceled grants deemed to focus on gender identity or diversity, equity and inclusion. In a hearing Monday on two cases calling for the grants to be restored, the judge pushed government lawyers to offer a formal definition of DEI, questioning how grants could be canceled for that reason when some were designed to study health disparities as Congress had directed. Young, an appointee of Republican President Ronald Reagan, went on to address what he called 'a darker aspect' to the cases, calling it 'palpably clear' that what was behind the government actions was 'racial discrimination and discrimination against America's LGBTQ community.' After 40 years on the bench, 'I've never seen government racial discrimination like this,' Young added. He ended Monday's hearing saying, 'Have we no shame.' During his remarks ending the hearing, the judge said he would issue his written order soon. Young's decision addresses only a fraction of the hundreds of NIH research projects the Trump administration has cut — those specifically addressed in two lawsuits filed separately this spring by 16 attorneys general from Democratic states, public health advocacy groups and some affected scientists. A full count wasn't immediately available. In the California lawsuit, filed in April with the other Democratic states, Atty. Gen. Rob Bonta said the UC system had received more than $2 billion in NIH awards in 2024 and that CSU had spent more than $90 million on NIH-funded research the same year. At the time of filing, Bonta wrote that the UC system's five health centers were awaiting action on grant proposals totaling $563 million. While Young said the funding must be restored, Monday's action was an interim step as the ruling could be appealed. The Trump administration is 'exploring all legal options' including asking the judge to stay the ruling or appealing, said Andrew Nixon, a spokesman for NIH's parent agency, the Department of Health and Human Services. 'HHS stands by its decision to end funding for research that prioritized ideological agendas over scientific rigor and meaningful outcomes for the American people,' he said in an email. While the original lawsuits didn't specifically claim racial discrimination, they said the new NIH policies prohibited 'research into certain politically disfavored subjects.' In a filing this month after the lawsuits were consolidated, lawyers said the NIH did not highlight genuine concerns with the hundreds of canceled research projects studies, but instead sent 'boilerplate termination letters' to universities. The topics of research ranged widely, including cardiovascular health, sexually transmitted infections, depression, Alzheimer's and alcohol abuse in minors, among other things. Attorneys cited projects such as one tracking how medicines may work differently in people of ancestrally diverse backgrounds, and said the cuts affected more than scientists — such as potential harm to patients in a closed study of suicide treatment. Lawyers for the federal government said in a court filing earlier this month that NIH grant terminations for DEI studies were 'sufficiently reasoned,' adding later that 'plaintiffs may disagree with NIH's basis, but that does not make the basis arbitrary and capricious.' The NIH, lawyers argued, has 'broad discretion' to decide on and provide grants 'in alignment with its priorities' — which includes ending grants. Monday, Justice Department lawyer Thomas Ports Jr. pointed to 13 examples of grants related to minority health that NIH either hadn't cut or had renewed in the same time period — and said some of the cancellations were justified by the agency's judgement that the research wasn't scientifically valuable. The NIH has long been the world's largest public funder of biomedical research. Neergaard writes for the Associated Press. Times staff writer Jaweed Kaleem contributed to this story.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store